(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 732MM | -2% |
Gross Profit | 278.2MM | -4% |
Cost Of Revenue | 453.8MM | -1% |
Operating Income | 160.9MM | -9% |
Operating Expenses | 117.3MM | - |
Net Income | 137MM | -15% |
R&D | 18.4MM | +12% |
G&A | 90MM | +1% |
Interest Expense | 1.2MM | -59% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Key Insights West Pharmaceutical Services' Annual General Meeting to take place on 23rd of April Salary of US$1.14m is...
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “Mid Cap Growth Strategy” investor letter, a copy of which can be downloaded here. The strategy outperformed its benchmark Russell Midcap Growth Index in the quarter. The strategy gained nine of the 11 sectors it was invested in during the quarter on an absolute basis. Overall […]
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.